News
All 17 experts recently dismissed from a government vaccine advisory panel published an essay Monday decrying “destabilizing ...
For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.
Investing.com -- A senior scientist at the U.S. Centers for Disease Control and Prevention (CDC) resigned Monday, expressing concerns about how COVID-19 and RSV hospitalization data would be used by ...
Fiona Havers, who oversees CDC respiratory virus data, told colleagues she no longer had confidence the data would be used ...
A Seattle infectious disease doctor, whose work was pivotal early in the COVID pandemic, shares more on her experience with ...
A U.S. government scientist who oversees the team responsible for collecting data on COVID-19 and RSV hospitalizations used ...
Explore more
5h
Zacks Investment Research on MSNEMA Accepts GSK's Filing for Expanded Use of RSV Vaccine ArexvyGSK plc GSK announced that the European Medicines Agency (EMA) has accepted the regulatory application seeking approval to ...
Tourists in Israel and Lebanon have found themselves stranded at airports amid Israel's conflict with Iran. Fiona Jones ...
Secretary of Health and Human Services Robert F. Kennedy Jr.’s decision to fire the Centers for Disease Control and ...
The incidence of RSV across 5 respiratory virus seasons was substantial among adult patients with high-risk underlying conditions.
Respiratory Syncytial Virus is a growing health concern for Indian infants. Efforts for maternal RSV vaccine faces challenges ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results